PharmiWeb.com - Global Pharma News & Resources
13-Dec-2023

Drägerwerk AG & Co. KGaA: Annual forecast raised again

Drägerwerk AG & Co. KGaA / Key word(s): Change in Forecast
Drägerwerk AG & Co. KGaA: Annual forecast raised again

13-Dec-2023 / 18:41 CET/CEST
Correction of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Annual forecast raised again

Lübeck, December 13, 2023 – Dräger's net sales and earnings in the current fourth quarter of 2023 have so far exceeded the Company’s expectations. This is due to continued high net sales recognition with high-margin products and effective cost management. Dräger therefore expects to exceed its previous forecast for fiscal year 2023. Accordingly, net sales could even grow by more than 11.0 percent net of currency effects, which corresponds to nominal growth of more than 8.5 percent, and EBIT could reach more than 4.0 percent of consolidated net sales.

In October, Dräger had already raised its forecast for the EBIT margin to between 2.0 and 4.0 percent due to the positive business development. The original forecast range for fiscal year 2023 was for currency-adjusted net sales growth of between 7.0 and 11.0 percent and an EBIT margin of 0.0 to 3.0 percent.

The preliminary figures for the 2023 fiscal year will be published in mid-January 2024. The 2023 Annual Report will be published on March 7, 2024.

 

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com

 

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

 

Corporate Communications:
Melanie Kamann
Tel. +49 451 882-3998
melanie.kamann@draeger.com

 

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company's knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.



End of Inside Information

Information and Explanation of the Issuer to this announcement:

Correction of an editorial error: The original net sales forecast for the 2023 fiscal year was not for currency-adjusted net sales growth of between 8.0% and 11.0%, but for currency-adjusted net sales growth of between 7.0% and 11.0%.

13-Dec-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck
Germany
Phone: +49 (0)451 882-0
Fax: +49 (0)451 882-2080
E-mail: info@draeger.com
Internet: www.draeger.com
ISIN: DE0005550602, DE 000 555 063 6, DE 000 555 071 9
WKN: 555060, 555063 Vorzüge, 555071 Genussschein D
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Stuttgart, Tradegate Exchange
EQS News ID: 1796421

 
End of Announcement EQS News Service

Editor Details

Last Updated: 13-Dec-2023